An amended beneficial ownership statement covering Common Shares of Robin Energy Ltd. was filed by Fouad Ahmed on November 6, 2026, disclosing a current beneficial ownership position of zero shares in the company.
First Financial Bancorp /OH/ filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 6, 2026, reporting consolidated financial results for the three and nine months ended September 30, 2026.
Autoliv Inc. EVP of HR and Sustainability Petra Albuschus filed a Form 4 on November 6, 2026, reporting the vesting of two tranches of restricted stock units and the acquisition of a combined 657 shares of common stock on that same date.
AIFU Inc. filed a Form 6-K with the SEC on November 6, 2026, reporting the completion of its acquisition of 100% of the equity interest in Waltz Investment Holding Ltd. through the issuance of consideration shares and a cash component to four sellers.
Uxin Ltd Chief Executive Officer and Director Dai Kun filed a Form 4 on November 6, 2026, disclosing a purchase of 8,307 American depositary shares of Uxin Ltd on November 5, 2026, made pursuant to a Rule 10b5-1(c) plan.
Immunocore Holdings plc filed a Form 8-K with the SEC on November 6, 2026, furnishing a press release announcing its financial results for the third quarter ended September 30, 2026, along with other recent corporate updates.
Protagonist Therapeutics, Inc. filed its quarterly report on Form 10-Q with the SEC on November 6, 2026, covering the fiscal quarter and nine-month period ended September 30, 2026.
Green Plains Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the Securities and Exchange Commission on November 6, 2026, reporting third-quarter net income attributable to the company of $85,436 thousand on revenues of $495,990 thousand.
Global Mofy AI Limited filed a Form 6-K with the U.S. Securities and Exchange Commission on November 6, 2026, reporting the completion of a registered direct offering of 45,000,000 Class A ordinary shares.
CG Oncology, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 6, 2026, reporting a net loss of $56.9 million for the third quarter and $196.1 million for the nine months ended September 30, 2026.